Search

Your search keyword '"Bélanger, Karl"' showing total 27 results
Start Over Author "Bélanger, Karl"
27 results on '"Bélanger, Karl"'

2. BIOS-02. CLINICAL OUTCOMES OF OVER 600 PATIENTS WITH GLIOBLASTOMA TREATED AT A CANADIAN TERTIARY CENTER IN THE PAST 15 YEARS: A COMPARATIVE ANALYSIS WITH THE PIVOTAL STUPP TRIAL

Author

Rousseau, Julien, primary, Desforges, Sara-Maude, additional, Jabbour, Gilbert, additional, Lemieux, Bernard, additional, Lapointe, Sarah, additional, Bélanger, Karl, additional, Moumdjian, Robert, additional, Cayrol, Romain, additional, Florescu, Marie, additional, Masucci, Giuseppina Laura, additional, Berthelet, France, additional, Lemieux-Blanchard, Émilie, additional, and Bahary, Jean-Paul, additional

Published
2022
Full Text
View/download PDF

3. Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors

Author

Tonneau, Marion, primary, Nolin-Lapalme, Alexis, additional, Kazandjian, Suzanne, additional, Auclin, Edouard, additional, Panasci, Justin, additional, Benlaifaoui, Myriam, additional, Ponce, Mayra, additional, Al-Saleh, Afnan, additional, Belkaid, Wiam, additional, Naimi, Sabrine, additional, Mihalcioiu, Catalin, additional, Watson, Ian, additional, Bouin, Mickael, additional, Miller, Wilson, additional, Hudson, Marie, additional, Wong, Matthew K., additional, Pezo, Rossanna C., additional, Turcotte, Simon, additional, Bélanger, Karl, additional, Jamal, Rahima, additional, Oster, Paul, additional, Velin, Dominique, additional, Richard, Corentin, additional, Messaoudene, Meriem, additional, Elkrief, Arielle, additional, and Routy, Bertrand, additional

Published
2022
Full Text
View/download PDF

4. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

Author

Stupp, Roger, Hegi, Monika E, Mason, Warren P, van den Bent, Martin J, Taphoorn, Martin JB, Janzer, Robert C, Ludwin, Samuel K, Allgeier, Anouk, Fisher, Barbara, Belanger, Karl, Hau, Peter, Brandes, Alba A, Gijtenbeek, Johanna, Marosi, Christine, Vecht, Charles J, Mokhtari, Karima, Wesseling, Pieter, Villa, Salvador, Eisenhauer, Elizabeth, Gorlia, Thierry, Weller, Michael, Lacombe, Denis, Cairncross, J Gregory, and Mirimanoff, René-Olivier

Published
2009
Full Text
View/download PDF

5. Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience

Author

Quinones, Maria Camila, primary, Bélanger, Karl, additional, Lemieux Blanchard, Émilie, additional, Lemieux, Bernard, additional, Bahary, Jean-Paul, additional, Masucci, Laura G., additional, Roberge, David, additional, Menard, Cynthia, additional, Lambert, Carole, additional, Berthelet, France, additional, Moumdjian, Robert, additional, and Florescu, Marie, additional

Published
2021
Full Text
View/download PDF

13. Adult Medulloblastoma Demographic, Tumor and Treatment Impact since 2006: A Canadian University Experience.

Author

Camila Quinones, Maria, Bélanger, Karl, Lemieux Blanchard, Émilie, Lemieux, Bernard, Bahary, Jean-Paul, Masucci, Laura G., Roberge, David, Menard, Cynthia, Lambert, Carole, Berthelet, France, Moumdjian, Robert, and Florescu, Marie

Subjects
*TUMOR treatment, *MEDULLOBLASTOMA, *ADULTS, *ADJUVANT chemotherapy, *BRAIN tumors, *PROGNOSIS
Abstract

Medulloblastoma is an aggressive primary brain tumor that is extremely rare in adults; therefore, prospective studies are limited. We reviewed the information of all MB patients treated at the CHUM between 2006 and 2017. We divided our cohort by age and further divided adult patients (53%) in two groups, those diagnosed between 2006-2012 and 2013-2017. In our adult population, median follow up was 26 months and SHH-activated MB comprised 39% of tumors. Adult 5yOS was 80% and first-line therapy led to a 5yPFS of 77%. The absence of radiosensitizing chemotherapy (100% vs. 50%; p = 0.033) negatively influenced 5yPFS. 96% of adult patients received radiotherapy and 48% of them received concomitant radiosensitizing chemotherapy. Complete surgical resection was performed on 85% of adults, but the extent of resection did not have a discernable impact on survival and did not change with time. Adjuvant chemotherapy did not clearly affect prognosis (5yOS 80% vs. 67%, p = 0.155; 5yPFS 78% vs. 67%, p = 0.114). From 2006-2012, the most common chemotherapy regimen (69%) was Cisplatinum, Lomustine and Vincristine, which was replaced in 2013 by Cisplatinum, Etoposide and Cyclophosphamide (77%) with a trend for worse survival. Nine patients recurred and seven of these (78%) were treated with palliative chemotherapy. In conclusion, we did not identify prognostic demographic or tumor factors in our adult MB population. The presence of radiosensitizing chemotherapy was associated with a more favorable PFS. Cisplatinum, Lomustine and Vincristine regimen might be a better adjuvant chemotherapy regimen. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

15. Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

Author

Jamal, Rahima, primary, Lapointe, Réjean, additional, Cocolakis, Eftihia, additional, Thébault, Paméla, additional, Kazemi, Shirin, additional, Friedmann, Jennifer E., additional, Dionne, Jeanne, additional, Cailhier, Jean-François, additional, Bélanger, Karl, additional, Ayoub, Jean-Pierre, additional, Le, Huy, additional, Lambert, Caroline, additional, El-Hajjar, Jida, additional, van Kempen, Léon C., additional, Spatz, Alan, additional, and Miller, Wilson H., additional

Published
2017
Full Text
View/download PDF

20. Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study

Author

Perry, James R., primary, Bélanger, Karl, additional, Mason, Warren P., additional, Fulton, Dorcas, additional, Kavan, Petr, additional, Easaw, Jacob, additional, Shields, Claude, additional, Kirby, Sarah, additional, Macdonald, David R., additional, Eisenstat, David D., additional, Thiessen, Brian, additional, Forsyth, Peter, additional, and Pouliot, Jean-François, additional

Published
2010
Full Text
View/download PDF

22. A phase II study of ispinesib (SB-715992) in patients with metastatic or recurrent malignant melanoma: a National Cancer Institute of Canada Clinical Trials Group trial

Author

Lee, Christopher W., primary, Bélanger, Karl, additional, Rao, Sanjay C., additional, Petrella, Teresa M., additional, Tozer, Richard G., additional, Wood, Lori, additional, Savage, Kerry J., additional, Eisenhauer, Elizabeth A., additional, Synold, Timothy W., additional, Wainman, Nancy, additional, and Seymour, Lesley, additional

Published
2007
Full Text
View/download PDF

23. Du théoricien au praticien Staline et la question nationale, le cas de la Géorgie

Author

Bélanger, Karl, Binette, Pierre, Bélanger, Karl, and Binette, Pierre

Abstract

Contrairement à ses prédécesseurs marxistes, Staline dut, d'une façon concrète et pratique, réconcilier le concept de reconnaissance des particularités nationales avec celui du développement de l'internationalisme prolétarien. Pour concilier la théorie à sa pratique du pouvoir, Staline légitima ses actions à l'aide des principes marxistes, principes qui furent ajustés en fonction de l'évolution contextuelle de l'URSS. À travers le cas de la Géorgie, nous verrons que l'attitude de Staline a contribué à la fois : à maintenir le fait national tout en promouvant les valeurs multinationales; et à gérer et réprimer les contradictions de type nationaliste tout en posant les conditions de leur survie, de leur exacerbation et de leur choc éventuel. L'exemple de la Géorgie illustre comment Staline, par des moyens violents, a tenté d'imposer les nouvelles valeurs multinationales (création de l'homo sovieticus) tout en maintenant le fait national (reconnaissance et représentation politique). La répression n'a pu suffire à éliminer les contradictions de type nationaliste en Géorgie, contribuant même à les renforcer, particulièrement entre les Russes et les nationaux d'une part, et entre les Géorgiens et les minorités nationales en Géorgie d'autre part. Le maintien du fait national --malgré les répressions-- fut particulièrement évident lors des manifestations de 1956 qui démontrèrent l'attachement des Géorgiens à leurs héros nationaux, notamment à Staline.

Published
1998

24. Helicobacter pyloriserology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors

Author

Tonneau, Marion, Nolin-Lapalme, Alexis, Kazandjian, Suzanne, Auclin, Edouard, Panasci, Justin, Benlaifaoui, Myriam, Ponce, Mayra, Al-Saleh, Afnan, Belkaid, Wiam, Naimi, Sabrine, Mihalcioiu, Catalin, Watson, Ian, Bouin, Mickael, Miller, Wilson, Hudson, Marie, Wong, Matthew K., Pezo, Rossanna C., Turcotte, Simon, Bélanger, Karl, Jamal, Rahima, Oster, Paul, Velin, Dominique, Richard, Corentin, Messaoudene, Meriem, Elkrief, Arielle, and Routy, Bertrand

Abstract

ABSTRACTThe microbiome is now regarded as one of the hallmarks of cancer and several strategies to modify the gut microbiota to improve immune checkpoint inhibitor (ICI) activity are being evaluated in clinical trials. Preliminary data regarding the upper gastro-intestinal microbiota indicated that Helicobacter pyloriseropositivity was associated with a negative prognosis in patients amenable to ICI. In 97 patients with advanced melanoma treated with ICI, we assessed the impact of H. pylorion outcomes and microbiome composition. We performed H. pyloriserology and profiled the fecal microbiome with metagenomics sequencing. Among the 97 patients, 22% were H. pyloripositive (Pos). H. pyloriPos patients had a significantly shorter overall survival (p = .02) compared to H. pylorinegative (Neg) patients. In addition, objective response rate and progression-free survival were decreased in H. pyloriPos patients. Metagenomics sequencing did not reveal any difference in diversity indexes between the H. pylorigroups. At the taxa level, Eubacterium ventriosum, Mediterraneibacter (Ruminococcus) torques, and Dorea formicigeneranswere increased in the H. pyloriPos group, while Alistipes finegoldii, Hungatella hathewayiand Blautia productawere over-represented in the H. pyloriNeg group. In a second independent cohort of patients with NSCLC, diversity indexes were similar in both groups and Bacteroides xylanisolvenswas increased in H. pyloriNeg patients. Our results demonstrated that the negative impact of H. pylorion outcomes seem to be independent from the fecal microbiome composition. These findings warrant further validation and development of therapeutic strategies to eradicate H. pyloriin immuno-oncology arena.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results